Comprehensive analysis of the cytokine-rich chromosome 5q31.1 region suggests a role for IL-4 gene variants in prostate cancer risk

Carcinogenesis

Volumn 31, Issue 10, 2010, Pages 1748-1754

  Tindall, E A ^a   Severi, G ^b,c   Hoang, H N ^b,c   Ma, C S ^a,d   Fernandez, P ^e   Southey, M C ^c   English, D R ^b,c   Hopper, J L ^c   Heyns, C F ^e   Tangye, S G ^a,d   Giles, G G ^b,c   Hayes, V M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b CANCER EPIDEMIOLOGY CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5;

ADULT; AGED; ALLELE; ARTICLE; AUSTRALIA; CANCER RISK; CANCER SUSCEPTIBILITY; CHROMOSOME 5Q; CHROMOSOME ANALYSIS; CHROMOSOME NOR; CONFIDENCE INTERVAL; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MALE; PLASMA; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

CHROMOSOMES, HUMAN, PAIR 5; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; INTERLEUKIN-4; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RNA, MESSENGER;

EID: 77957762680     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq081     Document Type: Article

References (51)

1. Baade, P.D. et al. (2009) International epidemiology of prostate cancer: geographical distribution and secular trends. Mol. Nutr. Food Res., 53, 171-184.
2. Fleshner, N.E. et al. (2009) Risk of developing prostate cancer in the future: overview of prognostic biomarkers. Urology, 73, S21-S27.
3. Vasto, S. et al. (2008) Inflammation and prostate cancer. Future Oncol., 4, 637-645.
4. Sutcliffe, S. et al. (2007) Inflammation in the etiology of prostate cancer: an epidemiologic perspective. Urol. Oncol., 25, 242-249.
5. De Marzo, A. et al. (1999) Proliferative Inflammatory Atrophy of the Prostate: implications for Prostatic Carcinogenesis. Am. J. Pathol., 155, 1985-1992.
6. Zabaleta, J. et al. (2008) Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis, 29, 573-578.
7. Zabaleta, J. et al. (2009) Cytokine genetic polymorphisms and prostate cancer aggressiveness. Carcinogenesis, 30, 1358-1362.
8. Zheng, S. et al. (2006) A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study. Prostate, 66, 1556-1564.
9. Witte, J.S. et al. (2000) Genomewide scan for prostate cancer-aggressiveness loci. Am. J. Hum. Genet., 67, 92-99.
10. Chu, L.W. et al. (2003) Genetic markers useful for distinguishing between organ-confined and locally advanced prostate cancer. Genes Chromosomes Cancer, 36, 303-312.
11. Kim, J.H. et al. (2007) Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res., 67, 8229-8239.
12. Takatsu, K. et al. (2009) Interleukin 5 in the link between the innate and acquired immune response. Adv. Immunol., 101, 191-236.
13. Wynn, T.A. (2003) IL-13 effector functions. Annu. Rev. Immunol., 21, 425-456.
14. Finkelman, F.D. et al. (1990) Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol., 8, 303-333.
15. Murphy, K. et al. (2002) The lineage decisions of helper T cells. Nat. Rev. Immunol., 2, 933-944.
16. Heikkinen, K. et al. (2006) RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis, 27, 1593-1599.
17. Heikkinen, K. et al. (2003) Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility. J. Med. Genet., 40, e131.
18. Swain, S.L. et al. (1990) IL-4 directs the development of Th2-like helper effectors. J. Immunol., 145, 3796-3806.
19. Muller-Hermelink, N. et al. (2008) TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell, 13, 507-518.
20. Giermasz, A.S. et al. (2009) Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunol. Immunother., 58, 1329-1336.
21. Lee, S.O. et al. (2009) Interleukin-4 activates androgen receptor through CBP/p300. Prostate, 69, 126-132.
22. Lee, S.O. et al. (2003) Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene, 22, 7981-7988.
23. Lee, S.O. et al. (2008) Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells. Prostate, 68, 85-91.
24. Takeshi, U. et al. (2005) Interleukin-4 in patients with prostate cancer. Anticancer Res., 25, 4595-4598.
25. Wise, G.J. et al. (2000) Cytokine variations in patients with hormone treated prostate cancer. J. Urol., 164, 722-725.
26. Rosenwasser, L. et al. (1995) Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Clin. Exp. Allergy, 25, 74-78.
27. Rosenwasser, L. et al. (1997) Genetics of atopy and asthma: the rationale behind promoter-based candidate gene studies (IL-4 and IL-10). Am. J. Respir. Crit. Care Med., 156, S152-S155.
28. Nakashima, H. et al. (2002) Association between IL-4 genotype and IL-4 production in the Japanese population. Genes Immun., 3, 107-109.
29. Tangteerawatana, P. et al. (2007) Relative levels of IL4 and IFN-gamma in complicated malaria: association with IL4 polymorphism and peripheral parasitemia. Acta Trop., 101, 258-265.
30. Noguchi, E. et al. (1998) Association of asthma and the interleukin-4 promoter gene in Japanese. Clin. Exp. Allergy, 28, 449-453.
31. Kawashima, T. et al. (1998) Linkage and association of an interleukin 4 gene polymorphism with atopic dermatitis in Japanese families. J. Med. Genet., 35, 502-504.
32. Vidyarani, M. et al. (2006) Interferon gamma (IFNgamma) & interleukin-4 (IL-4) gene variants & cytokine levels in pulmonary tuberculosis. Indian J. Med. Res., 124, 403-410.
33. Rezazadeh, M. et al. (2006) Association of susceptibility to brucellosis and interleukin-4 promoter polymorphism. Scand. J. Infect. Dis., 38, 1045-1049.
34. Kleinrath, T. et al. (2007) Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma. J. Clin. Oncol., 25, 845-851.
35. Landi, S. et al. (2007) Interleukin-4 and interleukin-4 receptor polymorphisms and colorectal cancer risk. Eur. J. Cancer, 43, 762-768.
36. Tsai, M.-H. et al. (2005) Interleukin-4 gene, but not the interleukin-1 beta gene polymorphism, is associated with oral cancer. J. Clin. Lab. Anal., 19, 93-98.
37. Severi, G. et al. (2003) ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer. J. Natl Cancer Inst., 95, 818-824.
38. AJCC: Prostate, A.J.C.o.C.. (2002) AJCC Cancer Staging Manual: TNM Classification of Malignant Tumours. Springer, New York.
39. Sham, P.C. (1998) Statistics In Human Genetics. Applications Of Statistics. Arnold, London.
40. Schaid, D.J. et al. (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am. J. Hum. Genet., 70, 425-434.
41. De Marzo, A. et al. (2007) Inflammation in prostate carcinogenesis. Nat. Rev. Cancer, 7, 256-269.
42. Loose, D. et al. (2009) The immune system and cancer. Cancer Biother. Radiopharm., 24, 369-376.
43. Ouyang, W. et al. (1998) Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity, 9, 745-755.
44. Quatan, N. et al. (2006) Persistently high levels of immunosuppressive cytokines in patients after radical prostatectomy. Prostate Cancer Prostatic Dis., 9, 420-425.
45. Hemmers, S. et al. (2009) T(H)2 bias: Mina tips the balance. Nat. Immunol., 10, 806-808.
46. Konwar, R. et al. (2008) Association of interleukin-4 and interleukin-1 receptor antagonist gene polymorphisms and risk of benign prostatic hyperplasia. Urology, 71, 868-872.
47. Sandell Sfanos, K. et al. (2008) Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin. Cancer Res., 14, 3254-3261.
48. Kramer, G. et al. (2002) Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate, 52, 43-58.
49. Martin, K. et al. (2006) Simultaneous analysis of cytokines and costimulatory molecules concentrations by ELISA technique and of probabilities of measurable concentrations of interleukins IL-2, IL-4, IL-5, IL-6, CXCL8 (IL-8), IL-10, IL-13 occurring in plasma of healthy blood donors. Mediators Inflamm., 2006, 65237.
50. Kabesch, M. et al. (2003) A complete screening of the IL4 gene: novel polymorphisms and their association with asthma and IgE in childhood. J. Allergy Clin. Immunol., 112, 893-898.
51. Bozzi, A. et al. (2009) Interferon-gamma and interleukin-4 single nucleotide gene polymorphisms in Paracoccidioidomycosis. Cytokine, 48, 212-217.